Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] A sense of excitement for a specific Lp(a)-lowering therapy

The discovery of lipoprotein(a) [Lp(a)] in 1963, followed by a more detailed biochemical characterisation in the 1970s, introduced a dazzling new lipoprotein composed of two components: an apolipoprotein (apo)B-containing low-density lipoprotein (LDL)-like particle, covalently linked to a plasminogen-like glycoprotein apo(a).1 During the next three decades, genetic approaches greatly advanced the understanding of this particle. Lp(a) is subject to tight genetic control, with more than 90% of its variance residing in the LPA gene encoding apo(a).